Veterinary Molecular Diagnostics Market Report 2026

Veterinary Molecular Diagnostics Market Overview

• Veterinary Molecular Diagnostics market size has reached to $0.7 billion in 2025 • Expected to grow to $1.11 billion in 2030 at a compound annual growth rate (CAGR) of 9.6% • Growth Driver: Rising Prevalence Of Zoonotic Diseases Fuels Growth In The Veterinary Molecular Diagnostics Market • Market Trend: Advancements In Veterinary Molecular Diagnostics With qPCR Technology In Early Disease Detection And Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Veterinary Molecular Diagnostics Market?

Veterinary molecular diagnostics refers to using molecular biology techniques to identify and diagnose animal diseases at a genetic or molecular level. These tests detect the presence of specific pathogens (such as bacteria, viruses, or parasites), genetic mutations, or biomarkers that indicate disease, helping veterinarians make accurate diagnoses and treatment plans. The main product types of veterinary molecular diagnostics include kits, reagents, and instruments. Kits and reagents are essential tools used in laboratories and industrial processes for conducting various diagnostic tests on animal samples, ensuring accurate and reliable results in diagnosing diseases and conditions in animals, which is crucial for effective treatment and management. The animal types include companion animals and livestock animals, and applications included are infectious diseases, genetic diseases, and others. The end users include diagnostic laboratories, veterinary clinics, veterinary hospitals, and others.

What Is The Veterinary Molecular Diagnostics Market Growth Forecast?

The veterinary molecular diagnostics market size is expected to see strong growth in the next few years. It will grow to $1.11 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to rising demand for rapid and accurate molecular diagnostics, adoption of ngs and high-throughput platforms, expansion of veterinary genomics services, integration of ai-driven diagnostic analysis, growing emphasis on preventive veterinary care through molecular testing. Major trends in the forecast period include expansion of pcr and rt-pcr-based diagnostics, growing adoption of next-generation sequencing (ngs) in veterinary medicine, development of multiplex diagnostic kits for infectious diseases, integration of molecular diagnostics in routine veterinary care, automation and high-throughput molecular testing solutions.

Global Veterinary Molecular Diagnostics Market Segmentation

1) By Product: Kits And Reagents, Instruments 2) By Animal Type: Companion Animals, Livestock Animals 3) By Application: Infectious Diseases, Genetic Diseases, Other Applications 4) By End-User: Diagnostic Laboratories, Veterinary Clinics, Veterinary Hospitals, Other End-Users Subsegments: 1) By Kits And Reagents: Polymerase Chain Reaction (PCR) Kits, Reverse Transcription PCR (RT-PCR) Kits, Real-Time PCR Kits, Nucleic Acid Extraction Kits, Enzyme-Linked Immunosorbent Assay (ELISA) Kits, Hybridization Kits, Reagents For Next-Generation Sequencing (NGS) 2) By Instruments: PCR Machines (Thermal Cyclers), Real-Time PCR Machines, Nucleic Acid Analyzers, Gel Electrophoresis Equipment, DNA Sequencers, Automated Liquid Handling Systems, Molecular Imaging Systems

What Is The Driver Of The Veterinary Molecular Diagnostics Market?

The high prevalence of zoonotic diseases is expected to propel the growth of the veterinary molecular diagnostics market going forward. Zoonotic diseases are infectious diseases that are transmitted between animals and humans. These diseases can be caused by bacteria, viruses, parasites, or fungi. Common zoonotic diseases include rabies, Lyme disease, salmonellosis, toxoplasmosis, and more. The prevalence of zoonotic diseases is influenced by deforestation, wildlife exploitation, intensive animal farming, biodiversity loss, and human mobility. Veterinary molecular diagnostics help detect zoonotic diseases early in animals, preventing their spread to humans. They also improve disease management by enabling rapid, accurate identification of pathogens. For instance, in December 2025, according to the European Centre for Disease Prevention and Control (ECDC), a Sweden-based government agency, in 2024, the number of reported human cases of key zoonotic diseases such as campylobacteriosis (168,396 cases) and salmonellosis (79,703 cases) continued to increase, reflecting a significant ongoing prevalence of zoonoses in Europe . Therefore, the high prevalence of zoonotic diseases is driving the veterinary molecular diagnostics industry.

Key Players In The Global Veterinary Molecular Diagnostics Market

Major companies operating in the veterinary molecular diagnostics market are Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Merck KGaA, Zoetis Inc., Illumina Inc., PerkinElmer Inc., bioMérieux S.A., IDEXX Laboratories Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., LGC Group Ltd., Neogen Corporation, Abcam plc, Eiken Chemical Co. Ltd., Bioneer Corporation, INDICAL BIOSCIENCE GmbH, Biochek B.V., Ring Biotechnology Co. Ltd., Ingenetix GmbH, MiDOG Animal Diagnostics LLC, Biolab S.r.l., Bionote USA Inc.

Global Veterinary Molecular Diagnostics Market Trends and Insights

Major companies operating in the veterinary molecular diagnostics market are focusing on automation and scalability in diagnostic technologies, such as high-volume testing machines, to improve diagnostic accuracy, increase testing efficiency, and enable faster detection of diseases in animals. High-volume testing machines are advanced diagnostic devices designed to process large quantities of samples efficiently, enabling rapid and accurate analysis in laboratories or clinical settings, particularly useful for large-scale testing. For instance, in June 2023, Iowa State University's Veterinary Diagnostic Laboratory (VDL), a US-based university, introduced SmartChip, a cutting-edge molecular diagnostic testing device equipped with quantitative polymerase chain reaction (qPCR) testing technology. This innovative device can accommodate more than 5,000 samples on a plate no bigger than a postage stamp. It greatly increases its testing capacity when paired with a 384-sample system equipped with automated handling features. The SmartChip testing utilizes microfluidic technology to identify targets of interest in samples, employing a volume 100 times smaller than that used by the VDL's standard 96-well machines.

What Are Latest Mergers And Acquisitions In The Veterinary Molecular Diagnostics Market?

In April 2023, Mars Incorporated, a US–based diversified manufacturing and petcare company, acquired Heska Corporation for approximately $1.3 billion. With this acquisition, Mars aimed to strengthen and expand its petcare science and diagnostics capabilities by broadening its veterinary diagnostic offerings and accelerating innovation in point-of-care solutions for the global pet healthcare market. Heska Corporation is a US–based healthcare technology company that specializes in developing, manufacturing, marketing, and supporting advanced veterinary diagnostic and specialty products and solutions for veterinary practitioners worldwide.

Regional Outlook

North America was the largest region in the Veterinary Molecular Diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Veterinary Molecular Diagnostics Market?

The veterinary molecular diagnostics market consists of revenues earned by entities by providing services such as diagnostic testing services, surveillance testing, genetic testing, toxicology, and biocompatibility testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The veterinary molecular diagnostics market also includes sales of immunoassay kits, diagnostic software, and next-generation sequencing (NGS) systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.